Potent Inhibitor of Human Trypsins from the Aeruginosin Family of Natural Products
Year of publication
2021
Authors
Ahmed, Muhammad N.; Wahlsten, Matti; Jokela, Jouni; Nees, Matthias; Stenman, Ulf-Håkan; Alvarenga, Danillo O.; Strandin, Tomas; Sivonen, Kaarina; Poso, Antti; Permi, Perttu; Metsä-Ketelä, Mikko; Koistinen, Hannu; Fewer, David P.
Abstract
Serine proteases regulate many physiological processes and play a key role in a variety of cancers. Aeruginosins are a family of natural products produced by cyanobacteria that exhibit pronounced structural diversity and potent serine protease inhibition. Here, we sequenced the complete genome of Nodularia sphaerocarpa UHCC 0038 and identified the 43.7 kb suomilide biosynthetic gene cluster. Bioinformatic analysis demonstrated that suomilide belongs to the aeruginosin family of natural products. We identified 103 complete aeruginosin biosynthetic gene clusters from 12 cyanobacterial genera and showed that they encode an unexpected chemical diversity. Surprisingly, purified suomilide inhibited human trypsin-2 and -3, with IC50 values of 4.7 and 11.5 nM, respectively, while trypsin-1 was inhibited with an IC50 of 104 nM. Molecular dynamics simulations suggested that suomilide has a long residence time when bound to trypsins. This was confirmed experimentally for trypsin-1 and -3 (residence times of 1.5 and 57 min, respectively). Suomilide also inhibited the invasion of aggressive and metastatic PC-3M prostate cancer cells without affecting cell proliferation. The potent inhibition of trypsin-3, together with a long residence time and the ability to inhibit prostate cancer cell invasion, makes suomilide an attractive drug lead for targeting cancers that overexpress trypsin-3. These results substantially broaden the genetic and chemical diversity of the aeruginosin family and suggest that aeruginosins may be a source of selective inhibitors of human serine proteases.
Show moreOrganizations and authors
University of Eastern Finland
Poso Antti
University of Helsinki
Poso Antti
Alvarenga Danillo O.
Fewer David P.
Koistinen Hannu
Jokela Jouni
Sivonen Kaarina
Wahlsten Matti
Ahmed Muhammad N.
Permi Perttu
Strandin Tomas
Stenman Ulf Håkan
Helsinki University Hospital
Poso Antti
Alvarenga Danillo O.
Fewer David P.
Koistinen Hannu
Jokela Jouni
Sivonen Kaarina
Wahlsten Matti
Ahmed Muhammad N.
Permi Perttu
Strandin Tomas
Stenman Ulf Håkan
Publication type
Publication format
Article
Parent publication type
Journal
Article type
Original article
Audience
ScientificPeer-reviewed
Peer-ReviewedMINEDU's publication type classification code
A1 Journal article (refereed), original researchPublication channel information
Journal/Series
Parent publication name
Volume
16
Issue
11
Pages
2537-2546
ISSN
Publication forum
Publication forum level
2
Open access
Open access in the publisher’s service
Yes
Open access of publication channel
Partially open publication channel
Self-archived
Yes
Other information
Fields of science
Chemical sciences; Pharmacy; Biochemistry, cell and molecular biology; Biomedicine; Cancers
Keywords
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Publication country
United States
Internationality of the publisher
International
Language
English
International co-publication
Yes
Co-publication with a company
No
DOI
10.1021/acschembio.1c00611
The publication is included in the Ministry of Education and Culture’s Publication data collection
Yes